Grace Therapeutics, Inc. Research And Development Expense

• Grace Therapeutics, Inc. showed an increase of +103.1% in Research And Development Expense from 2024 to 2025.
• This data is from Grace Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 23, 2025.
• XBRL data for this metric is available from 2016 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 12 years of available data (2016 to 2025), Grace Therapeutics, Inc.'s Research And Development Expense has grown by 25.7%.
• Historical annual values: Fiscal year 2025: $9.51 million | Fiscal year 2024: $4.68 million | Fiscal year 2023: $9.97 million | Fiscal year 2022: $5.56 million | Fiscal year 2021: $4.17 million | Fiscal year 2020: $15.97 million | Fiscal year 2019: $29.37 million | Fiscal year 2018: $15.67 million | Fiscal year 2017: $426.0 thousand | Fiscal year 2017: $7.65 million | Fiscal year 2017: $7.23 million | Fiscal year 2016: $7.57 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026